Home 2018-07-05T11:36:59+00:00

for a Brighter Tomorrow

JOIN MAILING LIST

PRESENTATION

PIPELINE

INVESTORS

ABOUT US

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.

PRESS RELEASES

Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

September 17th, 2019|Comments Off on Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

Topline data readout expected Q4 2019 NEW YORK, Sept. 17, 2019 [...]

Oramed to Present at Three Upcoming Conferences

September 3rd, 2019|Comments Off on Oramed to Present at Three Upcoming Conferences

NEW YORK, Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) [...]